More patients in the vicriviroc groups had undetectable virus at 48 weeks compared to those in the placebo group

Results showed that patients treated with 2 mg daily of TH9507 significantly improved their perception of belly image compared to the placebo group

Vical Inc., of San Diego, said licensee AnGes MG Inc., of Osaka, Japan, reported Phase III data strong enough for its angiogenesis product candidate that an independent monitoring committee recommended stopping the trial early due to ethical concerns about the placebo group...The primary endpoints, improvement of rest pain (VAS [Visual Analog Scale]) or ischemic ulcer size, at 12 weeks post dosing, showed 30.8% improvement in the placebo group and 70.4% improvement in the treatment group, a

In the Phase II trial, patients on pagoclone experienced a mean reduction in the percentage of syllables stuttered of 18 percent, compared to 5 percent for the placebo group...In the first three months of the open label trial, the originally treated patients achieved a 40 percent reduction, while the originally-placebo group achieved a 31 percent reduction

Patients treated with KW-3902 experienced a higher rate of improvement in dyspnea, a common symptom of CHF, compared to the placebo group, and the results also showed that the drug enhances diuresis and mitigates deterioration of renal function that is often experienced by patients undergoing standard treatment

Twenty-eight percent of patients in the DM/Q 45 arm and 27 percent in the DM/Q 30 arm obtained "a lot" or "complete" pain relief at three months vs. 17 percent in the placebo group (p=0.0008 and p=0.0017, respectively

XTL Biopharmaceuticals Ltd., of Valley Cottage, N.Y., said a 56-patient Phase I trial of XTL-2125 in patients with chronic hepatitis C showed that HCV-RNA viral load reductions were not significantly different from those seen in the placebo group

After six months of treatment, 70.5 percent of patients on 12.5 mg Androxal and 84 percent of patients on 25 mg Androxal achieved testosterone levels greater than 300 ng/dl, compared to 53.2 percent for the Androgel group and 31.9 percent for the placebo group

In the first three dose-escalation cohorts, 13 percent, 14 percent and 33 percent of patients receiving low, medium and high doses of tgAAC94, respectively, achieved a two-point reduction in swelling 12 weeks after treatment, compared to none in the placebo group

Among a defined subgroup of 39 patients identified as having more active disease - a score of greater than or equal to 250 on the Crohn's Disease Activity Index and C-reactive protein levels of greater than 7.5 mg/L at baseline - 58 percent in the Traficet-treated group experienced a 70-point or greater drop in CDAI scores compared to 31 percent in the placebo group...As reported earlier this year, data supported the dose response observed between the 100 mg, 300 mg and 900 mg, with the reductions

A previous Phase II study of MLN0002, derived from an earlier cell line, was well tolerated and achieved a statistically significant improvement, though there were reports of serious side effects mainly related to exacerbations of underlying ulcerative colitis occurring in 15 percent of patients in the treatment group compared to 10 percent in the placebo group

The average increase in walking speed over the treatment period, compared to baseline, was 25.2 percent for the drug-treated Timed Walk Responders vs. 4.7 percent for the placebo group

the placebo group...At week 24, the total cumulative mean number of gadolinium lesions per patient was reduced by 91 percent, to 0.5 in the Rituxan from 5.5 in the placebo group

Patients were randomized into seven drug-treated and placebo groups and challenged with gluten three times a day for 14 days

The new data showed that overall, 42 percent of patients on Flurizan showed improvement or no decline in one or more of the three primary endpoints of cognition, global function and activities of daily living, compared to 10 percent for the placebo group, indicating the drug may not only slow disease progression but also either halt that decline or even improve symptoms...There were no responders among the placebo group

At the time of the 18-month follow-up assessment, 15 (48 percent) patients in the Alpharadin group were still alive compared to six (22 percent) in the placebo group

Of those receiving 30 mg, 48 percent achieved the primary endpoint of clear or almost clear skin, compared to 28 percent in the 10 mg group and 17 percent in the placebo group

Dynogen Pharmaceuticals Inc., of Waltham, Mass., reported positive results from its Phase II trial of DDP733 in patients with irritable bowel syndrome with constipation, in which the drug achieved a statistically significant overall clinical response rate of 54 percent in those receiving 1.4 mg t.i.d compared to 15 percent for the placebo group...The company, however, reported that an improvement in baseline cartilage and joint condition was noted in about 30 percent of patients treated with the

Results, presented at the Keystone Symposium on Regulatory T Cells in Vancouver, British Columbia, showed that mice treated orally with HE3286 a week after disease onset had arthritis that nearly resolved or remained at minimum compared to the placebo group which steadily worsened